VIDEO: ONL1204 slows geographic atrophy lesion growth in phase 1b study
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Durga Borkar, MD, of Duke University Eye Center presents data from a phase 1b study investigating ONL1204, a Fas inhibitor, for geographic atrophy.
According to Borkar, the study had two components: an open-label dose-escalation study in which participants received one intravitreal injection of ONL1204 and a natural history and treatment portion in which GA lesion growth was monitored for 6 months before patients were randomly assigned to receive low-dose ONL1204, high-dose ONL1204 or sham.
The results were “very exciting and encouraging,” Borkar said, with ONL1204 demonstrating a reduction in the rate of GA lesion growth in both components of the study.
Collapse
Borkar D. Fas inhibition with ONL1204 for the treatment of geographic atrophy: First-time results from a phase 1b study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts